Peter E Schwartz MD

John Slade Ely Professor of Obstetrics, Gynecology, and Reproductive Sciences; Vice Chair, Gynecology; Section Chief, Gynecologic Oncology

Specialties & Subspecialties

Cancer Center, Yale: Gynecologic Oncology Program

Obstetrics, Gynecology & Reproductive Sciences: Gynecologic Oncology | Ovarian Cancer Program, Early Detection

Education & Training

  • M.D., Albert Einstein College (1966)
  • Resident, Yale-New Haven Hospital , Obstetrics & Gynecology 
  • Fellow, MD Anderson Cancer Center, Houston, Texas , Gynecologic Oncology 
  • Fellow, Yale University School of Medicine , Obstetrics & Gynecology 

Patient Care

Accepts New Patients? Yes | Patient Type: Adult, Child | Accepts referrals from patients


Clinical Interests

Ovarian, uterine, vaginal, cervical and vulvar cancer; Difficult gynecologic surgery; Screening for ovarian cancer; Gestational neoplasia; Brachytherapy


Board Certifications

  • Gynecologic Oncology, Board Certified (1979)
  • Obstetrics & Gynecology, Board Certified (1973)

Clinical Trials

Conditions Study Title
The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice of Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy.
A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer
A Randomized, Open-Label Study Comparing the Combination of YONDELIS® and DOXIL®/CAELYX® With DOXIL®/CAELYX® Monotherapy for the Treatment of Advanced Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
An open label Phase I dose escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose of the anti-mesothelin antibody drug conjugate BAY 94-9343 in subjects with advanced solid tumors

Edit Profile